ArticleAnnals of translational medicine2018

Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?

Robert W ChenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.